Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
66666688888完成签到,获得积分10
刚刚
lcy完成签到,获得积分10
1秒前
lixuebin完成签到,获得积分10
1秒前
Mae完成签到 ,获得积分10
1秒前
小冯完成签到,获得积分10
2秒前
WJDNG9完成签到,获得积分10
2秒前
诚心元菱发布了新的文献求助10
2秒前
Michael完成签到,获得积分10
2秒前
3秒前
友好语风完成签到,获得积分10
4秒前
潘润朗完成签到,获得积分10
5秒前
xiaopang完成签到,获得积分10
5秒前
俭朴的老头完成签到,获得积分10
6秒前
WJDNG7完成签到,获得积分10
6秒前
skearthy应助naiz采纳,获得40
7秒前
9秒前
风格化橙完成签到,获得积分10
9秒前
呆萌夏云完成签到,获得积分10
10秒前
下雨了完成签到,获得积分10
11秒前
凤英完成签到,获得积分10
11秒前
WJDNG1完成签到,获得积分10
11秒前
cdercder应助科研通管家采纳,获得10
11秒前
深情安青应助科研通管家采纳,获得10
11秒前
清野应助科研通管家采纳,获得10
11秒前
MozzieMiao应助科研通管家采纳,获得10
12秒前
Eins完成签到 ,获得积分0
12秒前
积极天川应助科研通管家采纳,获得10
12秒前
小怪兽完成签到,获得积分10
12秒前
molihuakai应助科研通管家采纳,获得10
12秒前
汉堡包应助科研通管家采纳,获得10
12秒前
完美世界应助科研通管家采纳,获得10
12秒前
搜集达人应助科研通管家采纳,获得10
12秒前
ding应助科研通管家采纳,获得10
12秒前
12秒前
赘婿应助科研通管家采纳,获得10
12秒前
lixuebin发布了新的文献求助10
12秒前
CodeCraft应助科研通管家采纳,获得10
12秒前
学院硕的开山大弟子完成签到,获得积分10
13秒前
13秒前
邓大瓜完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 2500
Roms fliessende Grenzen : Archäologische Landesausstellung Nordrhein-Westfalen 1000
Atlas of Aligner Treatment and Planning A Case-Based Approach 1000
Geist der Kunst und Kultur 1000
悉尼大学博士学位论文,题目:Modelling and testing of one-sided stitched laminated composites. 作者:Kristopher P. Plain 700
Soil mites of the family Rhagidiidae (Actinedida: Eupodoidea). Morphology, Systematics, Ecology 520
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7425379
求助须知:如何正确求助?哪些是违规求助? 9028433
关于积分的说明 19231922
捐赠科研通 7054069
什么是DOI,文献DOI怎么找? 3235664
关于科研通互助平台的介绍 2399112
邀请新用户注册赠送积分活动 2218178